Pilot Study of Bortezomib, Bendamustine and Rituximab for Patients With Relapsed or Refractory, Indolent or Mantle Cell Non-Hodgkin's Lymphoma.

Trial Profile

Pilot Study of Bortezomib, Bendamustine and Rituximab for Patients With Relapsed or Refractory, Indolent or Mantle Cell Non-Hodgkin's Lymphoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Nov 2011

At a glance

  • Drugs Bendamustine (Primary) ; Bortezomib (Primary) ; Rituximab (Primary)
  • Indications Chronic lymphocytic leukaemia; Follicular lymphoma; MALT lymphoma; Mantle-cell lymphoma; Waldenstrom's macroglobulinaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 Jan 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 13 Mar 2009 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.
    • 13 Mar 2009 Additional lead trial investigator identified as reported by ClinicalTrials.gov, last updated 13 Mar 2009.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top